newsfilter
← Latest News
GlobeNewswire·

Korro Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Started dosing healthy volunteers with KRRO-121 in the Phase 1/2 clinical trial (ANCHOR) Expect to dose participants with Urea Cycle Disorders (UCDs) in the first half of 2027Anticipate reporting interim data in the